Recently Introduced Products

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Indication</th>
<th>Potential Impact</th>
<th>Expected Avg. Annual Cost</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gelnique</td>
<td>For the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency</td>
<td>$</td>
<td>$1,022.00</td>
</tr>
</tbody>
</table>

$: Est. drug plan expenditure increase of <1%*  $$: Est. drug plan expenditure increase of 1-5%* $$$: Est. drug plan expenditure increase of >5%*

**Hello OxyNEO® - Goodbye OxyContin®**

Effective March 1, 2012, OxyContin® will be removed from the Canadian market and replaced with OxyNEO®. Although both products contain a long acting formulation of oxycodone, OxyNEO® because of its unique design is expected to lower the incidence of tampering, misuse and abuse. These tablets have been hardened during formulation. By doing so, the risk of breaking, crushing or chewing to extract the drug for illegal purposes has been diminished. For example, if crushed and added to water, the tablets result in a thick gel-like substance that prevents it from being extracted for injection purposes.

Narcotic drug abuse is a prevalent issue globally and has been a bane for both provincial government and private insurance drug plans. Overdoses involving prescription narcotics are responsible for 300 - 400 deaths per year in Ontario alone. Ontario has the highest rate of opioid use, and experienced an alarming 900% increase in oxycodone prescriptions between 1991 and 2009.¹

OxyContin® has been available as a Limited Use benefit on the Ontario Drug Benefit Formulary since 2000. In light of these issues, Ontario has not provided Limited Use access to OxyNEO® and is instead funding this drug through the Exceptional Access Program with specific criteria. OxyNEO® will also be available through the Facilitated Access Program. This program enables a select group of physicians (who have met pre-defined criteria) prescribe OxyNEO® for cancer and palliative care patients without an application process. This change in funding will help ensure appropriate prescribing and use of OxyNEO®.

Furthermore, the Atlantic Expert Advisory Committee has recommended that OxyNEO® not be listed on the Atlantic provincial drug plan formularies.² Thus, Nova Scotia, New Brunswick, Prince Edward Island, and Newfoundland and Labrador have restricted access to this drug. OxyNEO® will still be available in Nova Scotia on a case-by-case basis. Saskatchewan has placed it under Exception Drug Status thus limiting its use in cancer and palliative care patients.

OxyNEO® is available as 10mg, 15mg, 20mg, 30mg, 40mg, 60mg and 80mg tablets and is priced similar to OxyContin®. The daily cost of OxyNEO® ranges from $1.76 - $8.43. OxyNEO® will be fully covered under ClaimSecure’s standard drug plan and managed plans. ClaimSecure is committed to identifying members who have high narcotic usage per quarter, and where fraud activities are suspected.

*If you require additional information about OxyNEO®, please contact Lavina Viegas, Clinical Pharmacist, Clinical Services Department, at (905) 949-3031 or 1-888-479-7587 ext. 3031.*

**Recommendation: Full Coverage**

ClaimSecure reserves the right to amend in part or in its entirety stated special authorization clinical guidelines

References:

* Based on the Financial Impact Analysis per 100,000 lives covered © 2012 ClaimSecure Inc.